Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegpleranib
- Development stage
- Discontinued
- Lead developer
- Astellas Pharma
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal
01
Overview
Pegpleranib is a 32-mer pegylated DNA aptamer that selectively binds to platelet-derived growth factor subunit B (PDGF-B), inhibiting its interaction with PDGF receptors. By blocking PDGF-B, pegpleranib disrupts the recruitment of pericytes to endothelial cells, destabilizing abnormal blood vessels involved in neovascularization. This mechanism was investigated primarily for the treatment of neovascular (wet) age-related macular degeneration (AMD), often in combination with anti–vascular endothelial growth factor A (VEGF-A) therapies such as ranibizumab. Pegpleranib was developed by IVERIC bio and originated from Archemix Corporation, with additional development involvement from the National Eye Institute[2][4][7]. Clinical trials reached Phase III for wet AMD but were ultimately discontinued after failing to demonstrate sufficient efficacy[4][7].
- Brand names
- Fovista
- Other names
- pegpleranib sodium
02
Targets
PDGFB (PDGF-B)
Beyond the preview
Go deeper on pegpleranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegpleranib.